Home > Publications Database > Vesicular monoamine transport inhibitors: current uses and future directions. > print

001     280285
005     20250831001839.0
024 7 _ |a 10.1016/S0140-6736(25)01072-4
|2 doi
024 7 _ |a pmid:40783291
|2 pmid
024 7 _ |a 0140-6736
|2 ISSN
024 7 _ |a 0023-7507
|2 ISSN
024 7 _ |a 1474-547X
|2 ISSN
024 7 _ |a altmetric:180127743
|2 altmetric
037 _ _ |a DZNE-2025-00940
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Rosenthal, Liana S
|b 0
245 _ _ |a Vesicular monoamine transport inhibitors: current uses and future directions.
260 _ _ |a London [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756384389_10794
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Advancements over the past decade in understanding vesicular monoamine transporter 2 (VMAT2) inhibitors highlight their key role in the treatment of movement and neuropsychiatric disorders. VMAT2 is crucial for packaging neurotransmitters such as serotonin, dopamine, and norepinephrine into synaptic vesicles, facilitating their release and reuptake in synaptic transmission. VMAT2 inhibitors, such as tetrabenazine, deutetrabenazine, and valbenazine, show therapeutic efficacy in managing hyperkinetic movement disorders, including Huntington's disease, tardive dyskinesia, and Tourette's syndrome. These inhibitors modulate excessive synaptic activity by reducing neurotransmitter storage and release. Genetic variations, particularly in the cytochrome P450 enzyme family, influence VMAT2 inhibitor metabolism, necessitating personalised dosing to optimise efficacy and minimise adverse events. Recent studies have provided further structural insights into VMAT2 inhibition mechanisms, paving the way for the development of inhibitors with enhanced potency and selectivity. Leveraging pharmacogenetics for precision medicine and exploring VMAT2 inhibition in broader therapeutic contexts could revolutionise treatment frameworks for neurological and psychiatric conditions.
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Vesicular Monoamine Transport Proteins
|2 NLM Chemicals
650 _ 7 |a Tetrabenazine
|0 Z9O08YRN8O
|2 NLM Chemicals
650 _ 7 |a SLC18A2 protein, human
|2 NLM Chemicals
650 _ 7 |a deutetrabenazine
|0 P341G6W9NB
|2 NLM Chemicals
650 _ 7 |a valbenazine
|0 54K37P50KH
|2 NLM Chemicals
650 _ 7 |a Valine
|0 HG18B9YRS7
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Vesicular Monoamine Transport Proteins: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Vesicular Monoamine Transport Proteins: metabolism
|2 MeSH
650 _ 2 |a Tetrabenazine: analogs & derivatives
|2 MeSH
650 _ 2 |a Tetrabenazine: therapeutic use
|2 MeSH
650 _ 2 |a Tetrabenazine: pharmacology
|2 MeSH
650 _ 2 |a Huntington Disease: drug therapy
|2 MeSH
650 _ 2 |a Movement Disorders: drug therapy
|2 MeSH
650 _ 2 |a Valine: analogs & derivatives
|2 MeSH
700 1 _ |a Farag, Mena
|b 1
700 1 _ |a Aziz, N Ahmad
|0 P:(DE-2719)2812578
|b 2
|u dzne
700 1 _ |a Bang, Jee
|b 3
773 _ _ |a 10.1016/S0140-6736(25)01072-4
|g Vol. 406, no. 10503, p. 650 - 664
|0 PERI:(DE-600)1476593-7
|n 10503
|p 650 - 664
|t The lancet
|v 406
|y 2025
|x 0140-6736
856 4 _ |u https://pub.dzne.de/record/280285/files/DZNE-2025-00940_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/280285/files/DZNE-2025-00940_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:280285
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2812578
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF >= 90
|0 StatID:(DE-HGF)9990
|2 StatID
|b LANCET : 2022
|d 2024-12-16
920 1 _ |0 I:(DE-2719)5000071
|k AG Aziz
|l Population & Clinical Neuroepidemiology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000071
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21